1. Virus safety of solvent-detergent treated blood products;Horowitz,1993
2. Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency, Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via medicinal products, CPMP/BWP/877/96
3. Development and Characterisation of the High-Purity factor IX, Replenine;Feldman;Haemophilia,1995
4. Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency, note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/BWP/268/95, 1996